RELATING TO OFFICE OF ENTREPRENEURSHIP.

2025 Regular Session Introduced by Elle Cochran and 9 co-sponsors

House Bill 1442 empowers patients to choose their pharmacies freely, prohibits financial incentives from healthcare providers, and enhances access to pharmaceutical care in Arkansas.

Reported from ECD (Stand. Com. Rep. No. 335) as amended in HD 1, recommending passage on Second Reading and referral to FIN.

#appropriation($) #businesses #hawaiifilmandcreativeindustriesdevelopmentspecialfund #officeofentrepreneurship

Summary of House Bill 1442: Relating to the Office of Entrepreneurship

Bill Number: HB 1442
Introduced: February 10, 2025
Status: Reported from ECD (Stand. Com. Rep. No. 335) as amended in HD 1, recommending passage on Second Reading and referral to FIN.
Subject: Appropriation ($), Businesses, Hawaii Film and Creative Industries Development Special Fund, Office of Entrepreneurship

Purpose and Intent

House Bill 1442 aims to enhance the regulatory framework surrounding pharmacy contracting and conflicts of interest in Arkansas. The bill seeks to ensure patient freedom of choice in selecting pharmacies and pharmaceutical services, thereby improving access to care and quality of outcomes for patients.

Key Provisions

The bill introduces several significant provisions, including:

Prohibition of Conflicts of Interest:

Parent entities (such as hospitals and health centers) are prohibited from financially incentivizing patients to use specific pharmacies.
Restrictions are placed on limiting patient choices through financial incentives.

Patient Freedom of Choice:

Patients or their responsible parties are granted the right to choose their pharmacy or pharmacy treatment plan.
Documentation of the patient's choice must be maintained by the pharmacy permit holders.

Temporary Exemptions:

The Arkansas State Board of Pharmacy may issue temporary exemptions to specific permit holders for limited distribution or specialty item drugs to protect public health.

Market-Based Pricing:

The bill clarifies that market-based cash pricing for medications, independent of any contracts, does not constitute a financial incentive.

Patient Assistance Programs:

Programs that maximize pharmaceutical manufacturer cost assistance for patients are not considered violations of patient freedom of choice.

Affected Parties

Patients: The bill directly impacts patients by enhancing their ability to choose their pharmacy and ensuring they are informed of their options.

Pharmacies: Pharmacy permit holders must comply with the new regulations regarding patient choice and documentation.

Healthcare Providers: Hospitals and health centers with pharmacy interests will need to adjust their practices to align with the new restrictions on financial incentives.

Procedural Timeline

February 10, 2025: Bill introduced and passed the first reading.

February 11, 2025: Reported from ECD with amendments and referred to FIN.

February 26, 2025: Amendments adopted, and the bill was engrossed.

March 3, 2025: Passed the House and transmitted to the Senate.

May 5, 2025: Died in Senate Committee at Sine Die adjournment.

Conclusion

House Bill 1442 represents a significant step towards ensuring patient autonomy in pharmacy services while addressing potential conflicts of interest within the healthcare system. By establishing clear guidelines and protections, the bill aims to foster a more equitable and patient-centered approach to pharmaceutical care in Arkansas.